Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Net Cash Flow (2019 - 2025)

Keros Therapeutics (KROS) has disclosed Net Cash Flow for 7 consecutive years, with -$406.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 1488.37% year-over-year to -$406.1 million, compared with a TTM value of -$272.5 million through Dec 2025, down 218.99%, and an annual FY2025 reading of -$272.5 million, down 218.99% over the prior year.
  • Net Cash Flow was -$406.1 million for Q4 2025 at Keros Therapeutics, down from $3.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $160.6 million in Q1 2025 and bottomed at -$406.1 million in Q4 2025.
  • Average Net Cash Flow over 5 years is $1.1 million, with a median of $900500.0 recorded in 2022.
  • The sharpest move saw Net Cash Flow surged 5071.22% in 2023, then crashed 1488.37% in 2025.
  • Year by year, Net Cash Flow stood at $8.7 million in 2021, then skyrocketed by 355.84% to $39.6 million in 2022, then rose by 9.17% to $43.3 million in 2023, then plummeted by 32.38% to $29.2 million in 2024, then plummeted by 1488.37% to -$406.1 million in 2025.
  • Business Quant data shows Net Cash Flow for KROS at -$406.1 million in Q4 2025, $3.3 million in Q3 2025, and -$30.3 million in Q2 2025.